AN2 Therapeutics grants CMO 116K RSUs, options
AN2 Therapeutics’ chief medical officer received time-based RSU and stock option grants that vest over several years, conditioned on continued service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
AN2 Therapeutics, Inc. (ANTX) reported that Chief Medical Officer Trenor Cameron C. III received equity awards on September 15, 2026. He was granted 116,667 shares of Common Stock in the form of restricted stock units and a stock option covering 233,333 shares of Common Stock at an exercise price of $5.36 per share, expiring September 14, 2036. The RSUs and option vest over time, subject to his continuous service.
Insider Trade Summary
Grant/Award: 350,000 shares
Grant/Award
2 txns
Insider
Trenor Cameron C. III
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to by) F2 | 233,333 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 116,667 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to by) — 233,333 contracts (Direct);
Common Stock — 116,667 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units ("RSUs") which vest as follows: 10,400 RSUs vest on January 1, 2027, prorated from August 24, 2026, the vesting start date, and the remaining RSUs vest in equal annual installments on each January 1, 2028, January 1, 2029 and January 1, 2030, subject to the Reporting Person's continuous service through each applicable vesting date.
- F2. The shares subject to the stock option vest as follows: 25% of the shares vest on August 24, 2027 and the remaining shares vest in equal monthly installments over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.
Key Figures
RSUs granted: 116,667 shares
Stock option shares: 233,333 shares
Stock option exercise price: $5.36 per share
+3 more
6 metrics
RSUs granted
116,667 shares
Restricted stock units of Common Stock granted on September 15, 2026
Stock option shares
233,333 shares
Shares of Common Stock underlying option granted on September 15, 2026
Stock option exercise price
$5.36 per share
Exercise price for the 233,333-share option
Option expiration date
September 14, 2036
Expiration of stock option grant
Initial RSUs vesting
10,400 RSUs
Vest on January 1, 2027, prorated from August 24, 2026
Option cliff vesting
25% of 233,333 shares
Vests on August 24, 2027, before monthly vesting over 36 months
Key Terms
restricted stock units ("RSUs"), stock option, vesting start date, continuous service
4 terms
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") which vest as follows"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
stock option financial
"The shares subject to the stock option vest as follows"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting start date financial
"prorated from August 24, 2026, the vesting start date"
continuous service financial
"subject to the Reporting Person's continuous service through each"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did ANTX grant to its Chief Medical Officer on September 15, 2026?
AN2 Therapeutics granted Chief Medical Officer Trenor Cameron C. III 116,667 RSUs of Common Stock and a stock option for 233,333 shares of Common Stock at an exercise price of $5.36 per share, expiring on September 14, 2036.
How do the new RSUs granted by ANTX to the CMO vest?
The 116,667 RSUs vest as follows: 10,400 RSUs on January 1, 2027, prorated from the August 24, 2026 vesting start date, and the remaining RSUs vest in equal annual installments on January 1, 2028, January 1, 2029, and January 1, 2030, subject to continuous service.
What is the vesting schedule of the ANTX stock option granted to the CMO?
For the 233,333-share stock option, 25% of the shares vest on August 24, 2027, and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person’s continuous service through each vesting date.
What are the CMO’s holdings in ANTX after these grants?
After the grants, the reporting person directly holds 116,667 shares of Common Stock from RSUs and a stock option covering 233,333 shares of Common Stock, all subject to the stated vesting schedules and service conditions.
Were the ANTX equity grants to the CMO made under a Rule 10b5-1 trading plan?
The filing indicates the Rule 10b5-1 checkbox as not affirmed, and no footnote states otherwise, so these grants are reported without being identified as made under a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
